Brooks Automation (BRKS) received a Buy rating and a $72.00 price target from Needham analyst Stephen Unger today. The company’s shares closed last Monday at $54.57, close to its 52-week high of $54.90.
According to TipRanks.com, Unger is a 5-star analyst with an average return of 27.1% and a 75.7% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.
Currently, the analyst consensus on Brooks Automation is a Moderate Buy with an average price target of $57.25, which is an 8.8% upside from current levels. In a report issued on July 31, B.Riley FBR also maintained a Buy rating on the stock with a $65.00 price target.
See today’s analyst top recommended stocks >>
Based on Brooks Automation’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $220 million and net profit of $13.7 million. In comparison, last year the company earned revenue of $204 million and had a net profit of $7.25 million.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BRKS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brooks Automation, Inc. engages in the provision of automation and cryogenic solutions for multiple markets, including semiconductor capital equipment and life science biological sample management and storage. It operates through the Brooks Semiconductor Solutions Group and Brooks Life Sciences segments. The Brooks Semiconductor Solutions Group segment include atmospheric and vacuum robots, robotic modules and tool automation systems that provide precision handling and clean wafer environments, as well as cryogenic pumps and compressors that provide vacuum pumping and thermal management solutions used to create and control critical process vacuum applications. The Brooks Life Sciences segment provides automated cold sample management systems for compound and biological sample storage, equipment for sample preparation and handling, consumables, and parts and support services to a range of life science customers including pharmaceutical companies, biotechnology companies, bio-banks and research institutes. The company was founded in 1978 and is headquartered in Chelmsford, MA.
